Navigation Links
Manhattan Isotope Technology Completes Drug Master File With Federal Drug Administration
Date:8/22/2012

LUBBOCK, Texas, Aug. 22, 2012 /PRNewswire/ -- Positron Corporation, (OTCBB:POSC) a leading molecular imaging healthcare company, is pleased to announce the submission of a Drug Master File (DMF), with the Federal Drug Administration (FDA), for the production of Active Pharmaceutical Ingredient (API) grade strontium-82,  through its wholly owned subsidiary Manhattan Isotope Technology, LLC.

A Drug Master File (DMF) is a document submitted to the FDA, which contains complete information on an Active Pharmaceutical Ingredient (API) or finished drug dosage form. The DMF contains factual and complete information on a drug product's chemistry, manufacturer, stability, purity, impurity profile, packaging, and the cGMP status of any human drug product. The main objective of the DMF is to support regulatory requirements and to prove the quality, safety and efficacy of the medicinal product.

Manhattan Isotope's DMF submission initiates the protocol, procedures, and compliance required to produce Sr-82 for radiopharmaceutical applications, specifically for commercial use in Sr-82/Rb-82 generators.  Sr-82/Rb-82 generator manufacturers may now qualify MIT as a supply source and vendor for API grade Sr-82.   

Manhattan Isotope's DMF positions the Company as the only commercial entity in the United States in the Sr-82 processing and production arena.  Currently, the U.S. Department of Energy (DOE) is the only domestic supplier for many of the over 300 different isotopes, which are critical in medical, commercial, research, and national security applications.   Recent shortages have emphasized the importance of managing the demand for critical isotopes, substantiating Positron's timely entrance into this market. 

Jason Kitten, President of Manhattan Isotope Technology stated, "Our submission of the DMF is a very significant milestone, as it signifies Positron's evolution towards a vertically integrated nuclear medicine healthcare company.  Positron, through MIT, is the first private entity to demonstrate the expertise and ability to enter the market as a processor and supplier of API grade strontium-82.  Proficiencies in this segment are key to our end-to-end solution strategy.   Positron's ability to supply strontium and support production needs will not only stabilize the source supply of strontium-82, but will also lend growth to and strengthen the cardiac PET market as a whole."

About Positron: Positron Corporation is a leading molecular imaging healthcare company vertically integrating all the segments of nuclear cardiology—providing an end-to-end solution for cardiac PET.  Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology.  Positron is redefining the industry. More information about Positron is available at www.positron.com.

Forward Looking Statements:  Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Positron Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Water Isotope Analyzer Accurately Measures Contaminated Samples
2. Positron Consolidates Radiopharmaceutical & Radioisotope Facilities
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
5. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
6. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
7. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
8. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
9. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):